Navigation Links
InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
Date:5/18/2009

OXFORD, England, May 18 /PRNewswire/ -- PharmaVentures Ltd, announced today that it has been engaged by InDex Pharmaceuticals AB to advise and assist in out-licensing its first in class therapeutic, Kappaproct (DIMS 0150), for the treatment of steroid resistant / dependent Inflammatory Bowel Disease (IBD). The engagement will utilise PharmaVentures' transactions experience in the healthcare and investment business sectors.

Kappaproct, approved for Orphan Drug Designation in Europe, has recently successfully concluded its third clinical phase II trial for the treatment of Inflammatory Bowel Disease patients. Due to the highly positive interim results at both one and four weeks after dosing, this trial, which included 34 patients and was conducted as a multi-center study in Sweden and Russia, was concluded early. Kappaproct showed the same excellent safety profile as seen in previous trials.

Kappaproct is currently approved for clinical developmental use as a rectal, single-dose administration. Qualification of the compound for other routes of administration and multiple dosing is underway through an extended toxicology program.

Dr Fintan Walton, CEO, PharmaVentures commented, "PharmaVentures is very pleased to be involved in bringing this groundbreaking technology to the market. InDex are leaders in the field of immunomodulation via Toll Like Receptors."

InDex will be presenting Phase II data at BIO on Wednesday 20th May. See also InDex's Press Release released today: http://www.indexpharmab.com/images/pdf/kappaproctmay2009.pdf

Visit PharmaVentures during BIO at booths 4209 & 4211 for further information on this and other licensing opportunities.

    For enquiries about this opportunity, please contact:
    Dr Adrian Dawkes
    Managing Consultant
    PharmaVentures
    adrian.dawkes@pharmaventures.com
    +44 (0) 1865 784 193

Notes to Editors:

A leading results driven organisation, PharmaVentures (www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored consulting and transaction advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals range of intelligence products which include analysis tools and reports.

For further information please contact:

    Fiona Bishop
    PharmaVentures
    +44 (0) 1865 784 187
    fiona.bishop@pharmaventures.com

InDex Pharmaceuticals AB ("InDex") is a clinical stage biopharmaceutical company building a leading immunotherapy franchise based on its DIMS platform (DNA-based immunomodulatory sequence). DIMS drugs are developed to treat diseases within a variety of therapeutic areas, including inflammation and cancer. InDex has several proprietary DIMS compounds in various stages of development, including Kappaproct, for the treatment of steroid resistant/dependent ulcerative colitis.

    Svante Rasmuson, CEO
    Phone: +46 (0)8 50 88 47 31
    Mobile: +46 (0)708 63 93 31
    E-Mail: svante.rasmuson@indexpharmab.com

    Oliver von Stein, CSO
    Phone: +46 (0)8 50 88 47 32
    Mobile: +46 (0)708 93 33 75
    E-Mail: oliver.stein@indexpharmab.com

www.indexpharmab.com


'/>"/>
SOURCE PharmaVentures
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Standard & Poors Announces Changes to U.S. Index
2. Chicago-area Infertility Specialist Richard Sherbahn, MD, Reports a Woman's Body Mass Index Affects Her Success in Infertility Treatment
3. Cocaine Use Among U.S. Workers Declines Sharply in 2008, According to Quest Diagnostics Drug Testing Index(TM)
4. Chindex International, Inc. Announces May Conference Participation
5. ICW Master Patient Index Passes HITSP Certification and IHE Tests
6. SXC Health Solutions Added to S&P/TSX Composite Index
7. HCD Research and Muhlenberg College Will Use an Index to Monitor Physicians and Consumers Perceptions of Health Care Reform
8. MIB Life Index Reports North American Life Insurance Activity up 1.1% in February
9. Chindex International, Inc. to Participate in the Piper Jaffray & ChinaVenture Investment Conference 2009
10. Molecular Oncology accepted into Thomson Reuters index
11. Oridion Receives FDA 510(k) Clearance for Capnostream(TM)20 Monitor With Integrated Pulmonary Index(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... July 27, 2017 , ... Patients with missing teeth now ... office visit from Dr. Alejandro Kovacs. Dr. Kovacs is a board-certified periodontist and ... including Teeth-in-a-Day® dental implants in Longview, TX. , During traditional ...
(Date:7/27/2017)... Aliso Viejo, CA (PRWEB) , ... July 27, 2017 , ... ... Final Cut Pro X . This Final Cut Pro X exclusive features transitions that ... horizontally, and add rotation to the transition using intuitive drop-down menus. TransPanel Volume 4 ...
(Date:7/27/2017)... , ... July 27, 2017 , ... ... of a secure cloud-based polysomnography (PSG) distributed scoring solution to its healthcare management ... and sleep care management. The speed and functionality of scoring in the cloud ...
(Date:7/27/2017)... ... , ... SSCI, a division of Albany Molecular Research, Inc. ... a milestone achievement. , As an industry-leading provider of solid-state ... as expert and fact witnesses to assist our clients to perform infringement analyses, ...
(Date:7/27/2017)... ... July 27, 2017 , ... The Los Angeles leg of the US movie premier ... 7:00pm and will be held at the Clive Davis Theater inside the Grammy Museum Located ... chronicles the story of the iconic Welsh rock musician, Mike Peters (of The Alarm), his ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/14/2017)... 14, 2017 Endo International plc (NASDAQ: ENDP ... 8, 2017.  Members of its senior management team will host a ... 8:30 a.m. ET. The dial-in number to access ... (678) 509-7598, and the passcode is 45397076. Please dial in 10 ... A replay of the call will be available ...
(Date:7/13/2017)... , July 13, 2017  New York City-based market ... pharmaceutical markets should be aware of.  From new products to ... are detailed in a recently completed study, Potential Pipeline ... 1.  Age-Driven Growth - ... have been aware of the impact the growing population and, ...
Breaking Medicine Technology: